EUVIMEDEUVIMED entdecken
Systematische Übersicht

Prevalence of metabolic dysfunction‐associated steatotic liver disease in the Middle East and North Africa

Zobair M Younossi iD, Pegah Golabi iD, James Paik iD, Soroor Owrangi iD, Yusuf Yilmaz iD, Mohamed El-Kassas iD, Khalid Alswat iD, Saleh A Alqahtani iD

Liver International · 2024-04 · 44 (4) · 1061-1070

DOI: 10.1111/liv.15852 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Liver International, online erschienen am 02.02.2024. Verfasst von Zobair M Younossi und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Global NASH Council, Center for Outcomes Research in Liver Disease, Washington, DC, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 122-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Beatty Liver and Obesity Research Program, The Global NASH Council, The King Faisal Specialist Hospital and Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Metabolic dysfunction‐associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is common and closely associated with type 2 diabetes (T2D). We assessed the prevalence of NAFLD/MASLD in the general population and among patients with T2D in the Middle East and North Africa (MENA) region.

Methods

We searched PubMed and Embase for English‐language articles published between 1990 and 2023 according to PRISMA. Each country's NAFLD/MASLD prevalence in the general population and in T2D patients was predicted by using a multivariable meta regression model. Input data were extracted from our systematic review, GBD and NCD Risk Factor Collaboration. Confidence intervals were constructed by using prediction intervals with the delta method.

Results

Meta‐analytic pooling estimated the prevalence of NAFLD/MASLD as 39.43% in the general population and 68.71% among T2D patients. NAFLD/MASLD prevalence has increased from 35.42% (2008–2016) to 46.20% (2017–2020). Using GBD‐2019 dataset, it was predicted that there are 141.51 million cases of NAFLD/MASLD in the MENA region. The highest number of NAFLD/MASLD cases were expected in Egypt (25.71 million), followed by Türkiye (23.33 million) and Iran (19.85 million). Estimated NAFLD prevalence exceeded 40% in 10 of 21 countries with the top countries being Kuwait (45.37%), Egypt (45.0%), Qatar (44.4%), and Jordan (43.3%). Furthermore, it was predicted that there are 24.96 million cases of NAFLD/MASLD with T2D in the MENA region.

Conclusions

In the MENA region, prevalence of NAFLD/MASLD is very high and growing, necessitating an urgent need for regional public policy to deal with this growing burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Non-alcoholic Fatty Liver DiseaseHumansAfrica, NorthernMiddle EastPrevalenceRisk Factors

Stichwörter der Autor:innen

MASHMASLDMENAMiddle EastNAFLDNASHNorth AfricaT2Dsteatotic liver disease

Autor:innen und Institutionen

  • The Global NASH Council, Center for Outcomes Research in Liver Disease, Washington, DC, USA.
  • Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia, USA.
  • Department of Gastroenterology, School of Medicine, Recep Tayyip Erdoğan University, Rize, Turkey.
  • Department of Endemic Medicine, Faculty in Medicine, Helwan University, Cairo, Egypt.
  • Liver Disease Research Center, Department of Medicine, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia.
  • Division of Gastroenterology & Hepatology, Johns Hopkins University, Baltimore, Maryland, USA.

ORCID-Profile: Zobair M Younossi, Pegah Golabi, James Paik, Soroor Owrangi, Yusuf Yilmaz, Mohamed El-Kassas, Khalid Alswat, Saleh A Alqahtani

Förderung

  • Beatty Liver and Obesity Research Program
  • The Global NASH Council
  • The King Faisal Specialist Hospital and Research Centre

Zitieren

APA

Younossi, Z. M., Golabi, P., Paik, J., Owrangi, S., Yilmaz, Y., El-Kassas, M., Alswat, K., & Alqahtani, S. A. (2024). Prevalence of metabolic dysfunction‐associated steatotic liver disease in the Middle East and North Africa. Liver International, 44(4), 1061-1070. https://doi.org/10.1111/liv.15852

Vancouver

Younossi ZM, Golabi P, Paik J, Owrangi S, Yilmaz Y, El-Kassas M, et al. Prevalence of metabolic dysfunction‐associated steatotic liver disease in the Middle East and North Africa. Liver International. 2024;44(4):1061-1070. doi:10.1111/liv.15852

BibTeX
@article{Younossi2024,
  author = {Younossi, Zobair M and Golabi, Pegah and Paik, James and Owrangi, Soroor and Yilmaz, Yusuf and El-Kassas, Mohamed and Alswat, Khalid and Alqahtani, Saleh A},
  title = {Prevalence of metabolic dysfunction‐associated steatotic liver disease in the Middle East and North Africa},
  journal = {Liver International},
  year = {2024},
  volume = {44},
  number = {4},
  pages = {1061--1070},
  doi = {10.1111/liv.15852}
}
Kostenlos starten →